Global investors grappling with the fallout from the Iran war have slashed their expectations for economic growth by the most in four years, according to the latest Bank of America Corp. survey of fund managers. Expectations for inflation, meanwhile are at an almost five-year high, BofA strategists led by Michael Hartnett wrote in a note. Overall sentiment among investors is the most bearish since...
Global investors grappling with the fallout from the Iran war have slashed their expectations for economic growth by the most in four years, according to the latest Bank of America Corp. survey of fund managers. Expectations for inflation, meanwhile are at an almost five-year high, BofA strategists led by Michael Hartnett wrote in a note. Overall sentiment among investors is the most bearish since last June. The Middle East conflict, which began Feb. 28, has triggered a spike in oil and natural gas prices. That’s driving concerns higher energy costs will weaken growth and prompt central banks to increase interest rates to combat rising prices. Markets have been whipsawed as investors track the latest headlines on efforts at de-escalation. Hartnett said the survey findings are “contrarian positive for risk assets,” provided a ceasefire pushes the price of oil below $84 a barrel. In Tuesday’s trading, stocks rose and benchmark Brent crude fell below $99 as Iran and the US considered another round of peace talks. The survey was conducted April 2-9, among 170 participants overseeing $511 billion in assets. Three-fourths of investors responded before the April 8 announcement of a ceasefire, BofA said. Global growth expectations dropped by the most since the survey of March 2022, in the aftermath of Russia’s invasion of Ukraine, the latest poll shows. Even so, the S&P 500 Index erased its war-driven losses on Monday, while the Nasdaq 100 is poised for its longest streak of gains since 2021. “Investor macro expectations and US equity prices have once again diverged,” Hartnett wrote. Seven out of 10 survey participants still consider a recession to be unlikely and a majority continue to expect a “soft landing” for the global economy as the most likely scenario, according to the survey. Despite the potential “contrarian positive” signal, the strategists cautioned this was not a “close-eyes-and-buy” situation for markets. With investors still long global stocks, their positio...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
In recent trading, shares of TTM Technologies Inc (Symbol: TTMI) have crossed above the average analyst 12-month target price of $121.80, changing hands for $123.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
In recent trading, shares of TTM Technologies Inc (Symbol: TTMI) have crossed above the average analyst 12-month target price of $121.80, changing hands for $123.49/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
In recent trading, shares of T Rowe Price Group Inc. (Symbol: TROW) have crossed above the average analyst 12-month target price of $92.83, changing hands for $94.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
In recent trading, shares of T Rowe Price Group Inc. (Symbol: TROW) have crossed above the average analyst 12-month target price of $92.83, changing hands for $94.37/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade
In recent trading, shares of Equinix Inc (Symbol: EQIX) have crossed above the average analyst 12-month target price of $1036.60, changing hands for $1056.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valu
In recent trading, shares of Equinix Inc (Symbol: EQIX) have crossed above the average analyst 12-month target price of $1036.60, changing hands for $1056.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valu
In recent trading, shares of Steel Dynamics Inc. (Symbol: STLD) have crossed above the average analyst 12-month target price of $192.80, changing hands for $195.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o
In recent trading, shares of Steel Dynamics Inc. (Symbol: STLD) have crossed above the average analyst 12-month target price of $192.80, changing hands for $195.47/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade o
In recent trading, shares of Modine Manufacturing Co (Symbol: MOD) have crossed above the average analyst 12-month target price of $256.00, changing hands for $256.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrad
In recent trading, shares of Modine Manufacturing Co (Symbol: MOD) have crossed above the average analyst 12-month target price of $256.00, changing hands for $256.99/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrad
Check out the companies making the biggest moves premarket: Novo Nordisk — U.S.-listed shares popped 3% after the company announced a partnership with OpenAI . "Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever," Novo CEO Mike Doustdar said in a statement. ...
Check out the companies making the biggest moves premarket: Novo Nordisk — U.S.-listed shares popped 3% after the company announced a partnership with OpenAI . "Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously impossible, identify patterns we could not see, and test hypotheses faster than ever," Novo CEO Mike Doustdar said in a statement. JPMorgan Chase — The banking giant posted better-than-expected first-quarter results . JPMorgan Chase earned $5.94 per share on revenue of $50.54 billion. LSEG data shows analysts had penciled in a profit of $5.45 per share on revenue of $49.17 billion. However, the stock quickly gave back an initial gain and was down 2% after it lowered its net interest income guidance. Wells Fargo — Shares slid 1% after the company's first-quarter results failed to impress investors. The bank earned $1.60 per share, though that number was not comparable to an LSEG estimate of $1.58 as it includes a tax benefit. Revenue, meanwhile, was just below the analyst consensus at $21.45 billion. Johnson & Johnson — The pharma giant reported slightly better-than-expected results for the first quarter, sending shares up around 0.9%. J & J earned an adjusted $2.70 per share on revenue of $24.06 billion. Analysts expected a profit of $2.66 per share on revenue of $23.63 billion, per LSEG. Full-year earnings guidance was also slightly better than expected. BlackRock — The asset management giant climbed 1.7% on first-quarter earnings and revenue that beat the Street. BlackRock earned $12.53 per share on revenue of $6.7 billion. Analysts polled by LSEG expected a profit of $11.54 per share on revenue of $6.46 billion. United Airlines , American Airlines — United shares gained 2% following reports that CEO Scott Kirby had pitched a merger with American during a meeting with President Donald Trump. American Airlines shares advanced more than 4%. Intel — The chipmaker climbed 1%, putting it on pace for its 1...
CarMax press release ( KMX ): Q4 Non-GAAP EPS of $0.34 beats by $0.13 . Revenue of $5.95B (-0.8% Y/Y) beats by $220M . Combined retail and wholesale unit sales of 303,969, an increase of 0.7%. Bought 270,000 vehicles from consumers and dealers, an increase of 0.4%. 229,000 vehicles were purchased from consumers, up 2.5% 41,000 vehicles were purchased through dealers, down 9.5% Shares -2% PM. More ...
CarMax press release ( KMX ): Q4 Non-GAAP EPS of $0.34 beats by $0.13 . Revenue of $5.95B (-0.8% Y/Y) beats by $220M . Combined retail and wholesale unit sales of 303,969, an increase of 0.7%. Bought 270,000 vehicles from consumers and dealers, an increase of 0.4%. 229,000 vehicles were purchased from consumers, up 2.5% 41,000 vehicles were purchased through dealers, down 9.5% Shares -2% PM. More on CarMax CarMax: Starboard Value's Letter Highlights Important Topics CarMax: Downgrade To Sell On Unjustified Valuation Multiple CarMax Q4 2026 Earnings Preview Stocks to watch after market on Thursday: CRWV, CDNL, and KMX Seeking Alpha’s Quant Rating on CarMax
*Other Operating Data Consensus Source: Bloomberg More on Johnson & Johnson Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M ...
*Other Operating Data Consensus Source: Bloomberg More on Johnson & Johnson Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Johnson & Johnson Q1 preview: What to expect
More on Johnson & Johnson Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Johnson & Johnson Q1 preview: What to expect
More on Johnson & Johnson Johnson & Johnson Q1 Earnings Preview: Time To Sell The Rally? Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030 Johnson & Johnson: Is The Stock Still Undervalued After The Rally? A Quantitative Approach Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Johnson & Johnson Q1 preview: What to expect